Hims & Hers Health, Inc.

**Signal Note: Casdin Capital Initiates HIMS Position** Casdin's $12.5M entry into Hims & Hers suggests conviction in the telehealth platform's GLP-1 distribution opportunity, which has become a material revenue driver alongside chronic disease management. The position timing aligns with sustained demand for semaglutide/tirzepatide access and potential regulatory tailwinds around direct-to-consumer pharmaceutical distribution, though the lack of disclosed catalyst indicates this is a longer-term thesis rather than event-driven.